References
- Yao Y, Zhang JT, Yan B, et al. Voriconazole: a novel treatment option for cryptococcal meningitis. Infect Dis (Lond). 2015;47:694–700.
- Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291–1302.
- Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322.
- Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol. 2014;6:169–182.
- O'Connor L, Livermore J, Sharp AD, et al. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis. 2013;208:351–361.
- Roberts J, Bingham J, McLaren AC, et al. Liposomal formulation decreases toxicity of amphotericin B in vitro and in vivo. Clin Orthop Relat Res. 2015;473:2262–2269.
- Rajasingham R, Rolfes MA, Birkenkamp KE, et al. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2012;9:e1001316.
- Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012;54:121–128.
- Trpkovic A, Pekmezovic M, Barac A, et al. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia. J Mycol Med. 2012;22:243–248.
- van Duin D, Cleare W, Zaragoza O, et al. Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother. 2004;48:2014–2020.
- Gazzoni AF, Capilla J, Mayayo E, et al. Efficacy of intrathecal administration of liposomal amphotericin B combined with voriconazole in a murine model of cryptococcal meningitis. Int J Antimicrob Agents. 2012;39:223–227.
- Silva EG, Paula CR, Dias AL, et al. Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans. Mycopathologia. 2011;171:26–36.